Tesamorelin and CJC-1295 are both growth-hormone-releasing hormone (GHRH) analogs. They act at the same receptor: the GHRH receptor on pituitary somatotrophs: but their structural modifications produce substantially different pharmacokinetic profiles, and choosing between them shapes the entire experimental design.
This guide compares both compounds from a research mechanism perspective, with particular attention to the half-life differences that make each one appropriate for different study designs. All information is for research purposes only. These compounds are sold for research use only (RUO) and are not intended for human or veterinary use.
What Is Tesamorelin?
Tesamorelin is a synthetic GHRH analog consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group attached at the N-terminus. This modification confers resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, the primary enzyme responsible for rapid GHRH degradation in plasma. The result is a half-life of approximately 26 minutes: modest compared to native GHRH but substantially extended compared to unmodified GHRH 1-44.
Tesamorelin acts exclusively at GHRHR and preserves the physiological somatostatin feedback regulation of GH secretion. GH release remains pulsatile. Tesamorelin has an extensive clinical trial history, particularly in HIV-associated lipodystrophy research, making it one of the best-characterized GHRH analogs in terms of available reference data.
What Is CJC-1295?
CJC-1295 refers to a GHRH analog based on the first 29 amino acids of GHRH (GHRH 1-29, also called Modified GRF 1-29), with amino acid substitutions at positions 2, 8, 15, and 27 that confer DPP-IV resistance and improve stability. CJC-1295 exists in two pharmacologically distinct forms that researchers must distinguish:
- CJC-1295 without DAC (also called Modified GRF 1-29, Mod GRF 1-29): The modified GHRH 1-29 fragment without the drug affinity complex. Half-life approximately 30 minutes. Produces pulse-pattern GH release. Functionally similar in half-life profile to Tesamorelin.
- CJC-1295 with DAC: The same modified peptide with a maleimidopropionic acid (MPA) Drug Affinity Complex appended, enabling covalent albumin binding. The albumin-bound form has a half-life of approximately 8 days. This fundamentally changes the pharmacokinetic profile and produces sustained rather than pulsatile GH elevation.
The DAC modification makes CJC-1295 with DAC pharmacologically distinct not just from Tesamorelin but from CJC-1295 without DAC. Our CJC-1295 DAC vs No DAC research guide covers this distinction in depth.
Tesamorelin vs CJC-1295 Without DAC
Comparing Tesamorelin to CJC-1295 without DAC is the most mechanistically parallel comparison, since both are GHRH receptor agonists with similar half-lives:
- Half-life: Tesamorelin ~26 minutes; CJC-1295 without DAC ~30 minutes. The difference is minimal for most research designs.
- Peptide length: Tesamorelin is based on the full 44-amino-acid GHRH sequence; CJC-1295 without DAC is based on the 29-amino-acid fragment. Both retain full biological activity at GHRHR.
- DPP-IV resistance mechanism: Tesamorelin’s resistance comes from its N-terminal trans-3-hexenoic acid modification; CJC-1295 without DAC achieves DPP-IV resistance through amino acid substitutions at positions 2, 8, 15, and 27.
- GH release pattern: Both produce pulsatile GH release consistent with physiological GHRH signaling. Somatostatin feedback remains intact for both.
- Available reference data: Tesamorelin has significantly more published clinical trial data. CJC-1295 without DAC has extensive preclinical data and some clinical pharmacokinetic studies.
For researchers who want pulse-pattern GH stimulation and need to reference established clinical pharmacology, Tesamorelin may be preferred. For researchers primarily interested in GHRH analog pharmacology without the lipodystrophy-specific research context of most Tesamorelin trials, CJC-1295 without DAC is an equally well-characterized tool.
Tesamorelin vs CJC-1295 With DAC
This comparison involves fundamentally different pharmacokinetic profiles. CJC-1295 with DAC has a half-life of approximately 8 days due to covalent albumin binding via the DAC modification. A single administration produces sustained GH and IGF-1 elevation over a week-long window. Tesamorelin, with its 26-minute half-life, produces a transient pulse.
The research question dictates which profile is appropriate:
- Studies examining acute GH pulse dynamics, physiological GHRH signaling, or time-resolved GH release require Tesamorelin or CJC-1295 without DAC. A compound with an 8-day half-life cannot be used to study GH pulse frequency or the acute response to a GHRH stimulus.
- Studies examining sustained GH and IGF-1 elevation over extended periods, including metabolic consequences of prolonged GH axis activation, are better served by CJC-1295 with DAC. Its long half-life reduces administration frequency in long-duration studies, which is a practical advantage in animal model designs.
Selectivity and Off-Target Effects
Both Tesamorelin and CJC-1295 (in either form) are selective GHRHR agonists. Neither has documented significant activity at ghrelin receptors, insulin receptors, or other GH-axis receptor populations. Their off-target profiles are minimal compared to non-selective GH secretagogues.
The main pharmacological difference in terms of selectivity consequences is that CJC-1295 with DAC’s sustained GH elevation bypasses the pulsatile regulation that somatostatin normally imposes. Long-duration GH elevation studies may observe IGF-1 elevation patterns different from those seen with pulse-mimicking compounds, which is relevant when designing studies that reference physiological GH secretion patterns.
Research Design Summary
- Studying acute GHRH receptor pharmacology or GH pulse dynamics: Tesamorelin or CJC-1295 without DAC (similar half-life profiles, different reference data ecosystems)
- Studying sustained GH/IGF-1 elevation with reduced administration frequency: CJC-1295 with DAC
- Leveraging extensive clinical trial reference data: Tesamorelin (large lipodystrophy trial dataset)
- Combining with a GHS-R1a agonist (Ipamorelin) for dual-pathway studies: Either Tesamorelin or CJC-1295 without DAC paired with Ipamorelin; the GHRHR agonist choice depends on half-life preference for the pulse arm of the study
Frequently Asked Questions
Is Tesamorelin the same as CJC-1295?
No. Both are GHRH analogs and both act at GHRHR, but they differ in peptide length (44 vs 29 amino acids), the specific modifications conferring DPP-IV resistance, half-life, and available clinical reference data. They are related but distinct compounds. Tesamorelin should not be described as a form of CJC-1295 or vice versa.
Which has a longer half-life, Tesamorelin or CJC-1295?
It depends on which form of CJC-1295 is being compared. CJC-1295 without DAC has a half-life of approximately 30 minutes: similar to Tesamorelin at ~26 minutes. CJC-1295 with DAC has a half-life of approximately 8 days, far longer than Tesamorelin. The DAC modification is the defining pharmacokinetic variable for CJC-1295.
Can Tesamorelin and CJC-1295 be used together in a study?
Using both in the same model would mean two GHRH analogs competing for the same GHRHR receptor. This would produce competitive binding dynamics that complicate interpretation. Researchers generally do not combine two compounds acting at the same receptor unless studying receptor competition specifically. The more common dual-compound protocol pairs one GHRH analog with a GHS-R1a agonist like Ipamorelin, which activates a distinct receptor population.
Where can I find Tesamorelin clinical trial data?
The primary Tesamorelin clinical trial literature is in HIV-associated lipodystrophy studies. PubMed searches for “tesamorelin lipodystrophy” return the pivotal trials. The mechanistic overview of Tesamorelin is available in our Tesamorelin research guide. The DAC distinction for CJC-1295 is covered in detail in our CJC-1295 DAC vs No DAC research guide.
Research Compounds Available
Bastion Peptides supplies research-grade Tesamorelin, CJC-1295 with DAC, and CJC-1295 without DAC (Modified GRF 1-29) for qualified researchers. All compounds are sold for research use only and are not for human or veterinary use.
Mechanism Depth: GHRHR Signaling and Its Pharmacological Implications
Both Tesamorelin and CJC-1295 act through the GHRH receptor, and understanding the receptor’s signaling pathway explains both the compounds’ shared characteristics and their differences in duration of action.
The GHRH receptor is a class B G protein-coupled receptor (GPCR) that couples primarily to Gs proteins. Upon GHRH analog binding, Gs activates adenylyl cyclase, raising intracellular cAMP. cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including CREB (cAMP response element-binding protein). CREB drives GH gene transcription and stimulates GH secretory vesicle exocytosis from pituitary somatotrophs. This is the classical somatotroph activation pathway and is shared by all GHRH receptor agonists.
The practical implication of shared mechanism is that Tesamorelin and CJC-1295 (in either form) will produce the same quality of GHRH receptor activation but different quantities over time — because their half-lives determine how long the receptor remains occupied. Tesamorelin produces occupation for roughly 26 minutes before degradation; CJC-1295 without DAC for roughly 30 minutes; CJC-1295 with DAC for approximately 8 days (albumin-bound, gradual dissociation). The receptor itself is the same; the duration of signal is what differentiates the compounds’ pharmacological profiles in a study.
Somatostatin feedback deserves attention in protocol design. Somatostatin, released by hypothalamic periventricular neurons, inhibits GH release by binding somatostatin receptors (SSTRs) on pituitary somatotrophs and reducing cAMP. This feedback remains fully active during Tesamorelin and CJC-1295 administration because both compounds act at the GHRHR, not at the somatostatin receptor. The GH pulses produced by both compounds are therefore shaped by the prevailing somatostatin tone in the study animal. Models with high stress-induced somatostatin activity may show blunted GH responses to secretagogue administration, which is a biological variable researchers should measure or control for by including somatostatin inhibitor groups if hypothalamic regulation is a variable of interest.
Regulatory and Documentation Context
Tesamorelin has a notable regulatory history that provides researchers with exceptional reference data quality. It received FDA approval as Egrifta in 2010 for the treatment of HIV-associated lipodystrophy, making it the only GHRH analog with a completed New Drug Application dataset, including full Phase I pharmacokinetics, Phase II dose-finding, and Phase III pivotal efficacy and safety trials. This clinical development history means researchers can find more complete pharmacokinetic, pharmacodynamic, and safety data for Tesamorelin in the published clinical literature than for almost any other GHRH analog.
CJC-1295 with DAC has published clinical pharmacokinetic studies demonstrating its 8-day half-life and dose-dependent IGF-1 elevation, but does not have an approved drug application, and its published clinical dataset is smaller than Tesamorelin’s. CJC-1295 without DAC has extensive published preclinical data and is one of the most used GHRH analogs in animal model research, but clinical trial data is limited.
For researchers writing protocols that require citation of established pharmacology, Tesamorelin’s regulatory history provides an unusually deep reference data pool. For researchers prioritizing extended dosing intervals in animal models, CJC-1295 with DAC’s 8-day half-life is the practical choice. These are separate selection criteria that can both favor the same compound or different compounds depending on the study design.